狼疮肾炎患者血清sFas和sFasL的变化

目的　研究狼疮肾炎患者血清sFas和sFasL的变化及意义。方法　采用双抗体夹心酶联免疫吸附法 (ELISA)检测正常对照 18例和狼疮肾炎患者 45例血清sFas和sFasL水平。结果　狼疮肾炎患者sFas和sFasL水平分别为 (14± 7) μg/L和 (0 0 7± 0 0 4) μg/L ,与正常对照组 (2 9±1 2 ) μg/L和 (0 0 5± 0 0 1) μg/L相比 ,差异有高度显著性意义 (P <0 0 1)。活动期sFas水平较缓解期明显增高 ,分别是 (17± 7) μg/L和 (9± 4) μg/L ,P <0 0 1;但sFasL活动期与缓解期差异无显著意义。狼疮肾炎血清sFas水平在白细胞减少、贫血、大量蛋白尿、肾功能减退、补体降低、ANA和抗RNP Ab阳性时升高 ;而sFasL仅在肾功能异常时减低 ,与其他指标没有明显相关性。结论　sFas及sFasL参与了狼疮肾炎的发生 ,sFas可作为狼疮肾炎的活动性实验室指标。     

慢性心力衰竭患者的血清可溶性Fas配体和可溶性Fas受体

目的 分析血清可溶性Fas配体(sFasL)和可溶性Fas受体(sEas)与慢性心力衰竭(CHF)的相关性。方法采用酶联免疫吸附双抗体夹心法检测33例CHF患者(CHF组,心功能Ⅱ-Ⅳ级,NYHA)血清sFasL和sFas浓度,并与18例心功能Ⅰ级(NYHA)组比较。结果 CHF与心功能Ⅰ级间sFasL浓度无显著统计学差异[231.50±84.50(心功能Ⅱ级216.50±96.00,Ⅲ级226.80±85.70,Ⅳ级244.00±73.00)vs217.50±89.00pg/mL,P>0.05]。而CHF组血清sFas浓度显著高于心功能Ⅰ级组[1353.30±507.71(心功能Ⅱ级1154.85±371.20,Ⅲ级1412.88±493.62,Ⅳ级1875.67±806.10)vs983.11±461.26pg/mL,P<0.05]。结论 血清sFasL与CHF无相关性。而血清sFas与CHF存在显著相关性。且sFas浓度增高的程度与CHF的严重程度相平行,sFas浓度增高可能在CHF发病机制中起重要作用。     

可溶性Fas,可溶性Fas配体与细胞因子在1型糖尿病发病中的意义

目的　研究可溶性Fas(sFas)和可溶性Fas配体(sFasL)与细胞因子在1型糖尿病发病中的作用。方法　32名1型糖尿病患者和20名正常人的血清,采用夹心BAS-ELISA法分别检测sFas,sFasL,γ干扰素(IFN-γ)及白细胞介素-1(IL-1)含量。结果　1型糖尿病血清中sFas,IFN-γ及IL-1含量分别为(1　　546±685,1　　074±451与1　　406±721)ng/L,显著高于正常组;sFasL为(211±73)mg/L,低于正常组但差异无显著性。在1型糖尿病患者中高浓度sFas伴高IFN-γ者共12例,低浓度sFas伴低IFN-γ者共9例。结论　1型糖尿病患者血清中的sFas,IFN-γ及IL-1高于正常人,sFas与IFN-γ浓度呈正相关(r=0.79,P＜0.05)。对1型糖尿病患者血清进行sFas,IFN-γ及IL-1等检测可作为反映胰岛细胞病变的辅助指标,有助于对疾病的诊断与治疗。     

血清sFas、sFasL水平与特发性血小板减少性紫癜的关系

采用酶联免疫夹心法(ELISA)检测了25例特发性血小板减少性紫癜(ITP)患者血清中sFas、sFasL的水平.结果显示ITP患者血清sFas含量为16.51±6.86μg/L,sFasL含量为0.48±0.33μg/L,均显著高于正常对照(分别为P<0.001和P<0.01);18例ITP患者血清sFas水平升高,其中有9例同时有sFasL水平升高,但是血清sFas水平升高组的血小板计数与sFas正常组无显著差异.提示sFas和sFasL的异常参与了ITP的免疫病理过程.     

系统性红斑狼疮凋亡相关基因Fas、sFas mRNA表达研究

目的　从转录水平研究系统性红斑狼疮患者凋亡相关基因Fas、sFas表达情况 ,探索凋亡在SLE发病中的作用。方法　利用荧光标记RT PCR半定量方法 ,以 β actin为内参照 ,对 5 0例SLE、2 4例RA和 2 4名正常人外周血白细胞凋亡相关基因Fas、sFasmRNA表达水平进行了检测。结果　SLEFas、sFas表达均高于正常对照 ( 3 2± 1 8vs 2 1± 0 6,P <0 0 0 1和 1 2± 0 7vs 0 5 8±0 2 7,P <0 0 0 0 1) ,并且表达量与病情活动度相关 (相关系数分别为 0 5 2 18,P =0 0 0 7和 0 4 188,P =0 0 3 7) ,而RA仅sFas表达增高 ( 0 9± 0 5vs 0 5 8± 0 2 7,P <0 0 1)。结论　SLE患者外周血白细胞凋亡相关基因表达存在异常 ,提示凋亡在SLE发病中可能具有一定作用和意义。     

乙型肝炎病人血清转化生长因子α水平检测及其临床意义

目的　通过对不同病程的乙型肝炎病人血清转化生长因子α(TGF α)的检测 ,探讨TGF α的变化规律及其与肝功能损害的关系 ,并对TGF α在乙型肝炎诊断中的临床意义进行初步观察。方法　采用放射免疫分析法测定了 84例乙型肝炎患者血清TGF α含量 ,同时检测了各项肝功能指标。所获数据利用计算机SPSS软件应用方差分析及相关分析法进行统计学处理。结果　①急性肝炎、慢性肝炎 (中度 )、慢性肝炎 (重度 )病人血清TGF α含量分别为 13 744± 4 449pg/ml、12 815± 5 2 2 5pg/ml、15 892± 5 0 94pg/ml,明显高于对照组 8 3 95± 3 10 7pg/ml(P <0 0 1) ;慢性肝炎 (轻度 )病人血清TGF α含量为 8 517± 2 719pg/ml,与对照组比较差异无统计学意义 (P >0 0 5)。②肝病病人血清TGF α的变化与肝功能指标ALT、AST、ALB呈正相关关系 ,而与AKP、γ GT无关。结论　血清TGF α的检测对乙型肝炎的预后估计具有重要临床意义 ,且TGF α与肝功能损害程度相关     

人免疫缺陷病毒携带者和艾滋病患者血清IFN-γ、IL-10和免疫球蛋白的检测及其临床意义

目的　探讨IFN γ和IL 10在人免疫缺陷病毒 (HIV )感染中的意义。方法　利用双抗体夹心ELISA法检测 3 0例HIV携带者、16例艾滋病 (AIDS)患者血清IFN γ和IL 10水平 ,采用透射比浊法检测血清IgG、IgA和IgM水平 ,选择 2 3名健康人作对照组。 结果　AIDS患者IFN γ水平为 (4 .5± 2 .7)pg/ml,对照组为 (8.2± 4.1) pg/ml,AIDS患者明显低于对照组 (P <0 .0 5 ) ,HIV携带者、AIDS患者血清中IL 10水平明显高于对照组 [(12 .4± 7.4) pg/ml ,(2 8.1± 11.2 ) pg/mlVs(6.9± 3 .8)pg/ml ,P <0 .0 1] ,且AIDS组高于HIV携带组 (P <0 .0 1)。HIV携带者和AIDS患者血清中免疫球蛋白水平均高于对照组。结论　HIV携带者存在Th1型免疫应答缺陷 ,Th2型免疫应答与感染慢性化及疾病持续发展有关。     

自身免疫病患者外周血中B细胞激活因子基因表达水平的测定

目的　建立测定B细胞激活因子 (B lymphocytestimulator ,BlyS)mRNA含量的荧光定量反转录 聚合酶链反应 (RT PCR)法 ,并用来检测自身免疫病 [系统性红斑狼疮 (SLE)、类风湿关节炎 (RA) ]患者外周血单个核细胞 (PBMCs)中BlyS的基因表达水平 ,探讨BlyS基因表达水平与自身免疫性疾病发病机制的关系。方法　构建克隆载体 pMD18 T BlyS作为定量模板 ,基于TaqMan荧光探针技术 ,建立实时荧光RT PCR方法在GeneAmp 5 70 0型检测仪上定量检测 19例自身免疫病(SLE、RA)确诊病人、2 0例亚临床病人 (主要是抗核抗体阳性 )、8例其他对照性疾病患者 (自身抗体阴性 ,免疫球蛋白升高 )、2 0名正常健康献血者的外周血BlySmRNA表达含量。结果　 19例自身免疫病确诊病人的PBMCs中均有BlySmRNA的表达 ,范围从 9 7× 10 5～ 3 2× 10 8拷贝 /μgRNA ,均值为 (8 4± 7 9)× 10 7拷贝 /μgRNA ;2 0例亚临床病人的强度为 8 6× 10 4～ 3 8× 10 6拷贝 /μgRNA ,均值为 (1 3± 1 2 )× 10 6拷贝 /μgRNA ;2 0名正常健康人的强度为 5 5× 10 4～ 4 9× 10 5拷贝 /μgRNA ,均值为 (1 7± 1 4 )× 10 5拷贝 /μgRNA ;8例自身抗体阴性而免疫球蛋白升高的其他疾病患者的强度为 5 8× 10 5～ 3 5× 10 7拷贝 /μgRNA ,均值为 (1 2±     

系统性红斑狼疮患者血清中B淋巴细胞刺激因子的检测

目的检测系统性红斑狼疮(SLE)患者血清B淋巴细胞刺激因子(BLyS)水平,并探讨其在SLE发病中的意义。方法采用双抗体夹心酶联免疫吸附试验(ELISA)法检测血清BLyS水平。结果①SLE患者血清BLyS[(9.6±2.3)ng/ml]显著高于正常人对照组[(4.0±1.5)ng/ml]。②SLE患者中,血清BLyS水平活动组[(11.1±2.2)ng/ml]高于非活动组[(8.1±1.2)ng/ml],抗dsDNA抗体阳性组[(10.9±2.2)ng/ml]高于抗dsDNA抗体阴性组[(8.1±1.4)ng/ml],高IgG组[(10.8±2.4)ng/ml]高于非高IgG组[(8.3±1.3)ng/ml],低C3组[(10.2±2.5)ng/ml]高于非低C3组[(8.3±1.3)ng/ml],低C4组[(10.1±2.3)ng/ml]高于非低C4组[(7.6±0.7)ng/ml],低血小板计数组[(10.7±2.7)ng/ml]高于非低血小板计数组[(8.8±1.7)ng/ml]。③SLE患者血清BLyS水平与SLE疾病活动指数(SLEDAI)(r=0.56,t=15.89,P<0.01)、IgG(r=0.33,t=4.20,P<0.05)呈正相关;与C4(r=-0.47,t=10.04,P<0.01)、血小板计数(r=-0.53,t=13.85,P<0.01)呈负相关。结论BLyS可能参与SLE的发病。     

糖尿病合并阿尔茨海默病患者血清可溶性凋亡相关因子及其配体的表达及临床意义

目的 探讨糖尿病合并阿尔茨海默病(AD)患者血清可溶性凋亡相关因子(sFas)和sFasL配体(sFasL)表达及临床意义。方法 选取2020年5月至2021年12月鄂州市中心医院老年病科老年2型糖尿病(T2DM)患者130例，根据是否合并AD分为合并组65例和未合并组65例，另选取同期单纯AD患者65例作为单纯AD组，老年健康体检者65例为对照组。检测各组血清sFas、sFasL水平。结果 合并组血清sFas、sFasL水平高于单纯AD组、未合并组及对照组，单纯AD组血清sFas、sFasL水平高于未合并组及对照组，未合并组血清sFas、sFasL水平高于对照组(P<0.05);合并组痴呆重度患者血清sFas、sFasL水平高于中度患者及轻度患者，中度患者血清sFas、sFasL水平高于轻度患者(P<0.05);血清sFas、sFasL水平与T2DM患者临床痴呆评定量表评分呈正相关(r=0.773、r=0.689,P<0.01);血清sFas、sFasL联合检测诊断T2DM合并AD的ROC曲线下面积(AUC)为0.836(95%CI:0.761～0.895),明显高...     

Relationship between HBxAg and Fas/FasL in patients with hepatocellularcarcinoma

AIM To assess the relationship between HBV X-gene, X-gene product and Fas/ FasL which mediatehepatocellular apoptosis in patients with hepatocellular carcinoma.METHODS Tissue from 34 patients with hepatocellular carcinoma was tested for the expression of HBxAg.Quantitative ELISA assay was used to detect sFas; and sFasL and PCR were used to detect the HBV X-genein sera from 30 patients with hepatocellular carcinoma, 32 patients with liver cirrhosis and 20 normalcontrols.RESULTS The positive expression of HBxAg, Fas and FasL in carcinoma tissue was 97.06%, 85.29% and100%, respectively. The positive signal was mainly presented in the plasma, and all of these three positivestaining may appear in the same area. Redit analysis showed that there was no significant difference amongthese three positive staining (P >0.05). The mean levels of sFas in sera from hepatocellular carcinoma, livercirrhosis and normal controls were 722.97±321.12, 801.90±419.94 and 224.07±148.23, respectively,showing that sFas levels in patients with hepatocellular carcinoma and liver cirrhosis were significantlyelevated than that in normal controls (P < 0.0l). The mean levels of sFasL in sera from hepatocellularcarcinoma, liver cirrhosis and normal controls were 152.27±7.99, 162.97±12.40 and 154.99 ± 6.96,showing that sFasL level in patients with liver cirrhosis was significantly higher than that in patients withhepatocellular carcinoma and normal controls (P< 0.01). HBV X-gene was found to be positive in sera of30% patients with hepatocellular carcinoma; HBV X-gene was found to be positive in sera of 43.75% ofpatients with liver cirrhosis. There was no significant difference in sFas/sFasL level between HBV X-genepositive patients and HBV X-gene negative patients (P >0.05).CONCLUSION The expression of HBxAg and Fas/FasL in the tissue of hepatocellular carcinoma seemed tobe almost the same, but relation between cause and effect is unclear. The detection of sFas and sFasL inpatient sera may reflect the state of apoptosis mediated by Fas/FasL system. Our data showed that HBV X-gene expression in sera seemed to have no relation to sFas/sFasL level; however, these data also suggestedthat some patients with negative HBsAg in sera might have integrated HBV X-gene in liver tissues, andtherefore X-gene is detectable in those patient sera.     

Influence of levothyroxine treatment on serum levels of soluble Fas (CD95) and Fas Ligand (CD95L) in chronic autoimmune hypothyroidism

Fas/FasL-mediated apoptosis results in the destruction of thyrocytes in chronic autoimmune hypothyroidism (CAIH). In this study, we examined the serum levels of soluble Fas (sFas) and soluble sFas ligand (sFasL) in euthyroid patients with chronic autoimmune hypothyroidism, who were taking levothyroxine (euthyroid, LT4-CAIH), to investigate the possible role of thyroid hormone therapy in down-regulation of apoptotic factors. Fifty euthyroid patients with CAIH on levothyroxine (median of duration 36 months, range 6-228 months) were compared with 75 age- and sex-matched healthy individuals. Serum levels of soluble Fas and soluble Fas Ligand, autoantibodies to thyroid peroxide and thyroglobulin were measured using ELISA. Serum levels of sFas were significantly higher in the euthyroid, LT4-CAIH group [median 9.12 ng/ml, interquartile range (7.86-10.72 ng/ml)] than in the controls [6.11 ng/ml (5.60-6.81 ng/ml)] (P < 0.0001). Compared with controls [80.33 pg/ml (68.22-103.70 pg/ml)], the euthyroid, LT4-CAIH group [125.71 pg/ml (106.11-149.48 pg/ml)] had significantly higher levels of sFasL (P < 0.0001). In a chronological study, there was no significant correlation between sFas, sFasL, and the duration of levothyroxine therapy. In conclusion, normalization of serum sFas and sFasL levels cannot be achieved during levothyroxine treatment in patients with CAIH. It appears that levothyroxine therapy has no important effect on down-regulation of apoptotic factors in CAIH. Thus, like thyroid autoantibodies, monitoring of serum levels of sFas/sFasL is not indicated during thyroid hormone therapy.     

Elevation of soluble Fas and soluble Fas ligand in reactive macrophage activation syndromes

Derailed T-cell activation can give rise to life-threatening macrophage activation, the final common pathway of the different forms of reactive macrophage activation syndromes (rMAS). Besides inappropriate activation of the immune system, impaired termination of immune responses might be another mechanism leading to rMAS. The Fas (CD95)/Fas ligand (CD95 ligand) system functions in turning off immune responses by executing activation-induced cell death (AICD). Soluble Fas (sFas) and Fas ligand (sFasL) can interfere with their corresponding membrane-bound counterparts, qualifying them as potential parameters of impaired immune termination. Hence, sFas and sFasL were analyzed in sera of rMAS patients. We show that soluble Fas/CD95 (sFas) is elevated >2 SD over the mean of controls in all 8 rMAS episodes studied (mean 12.08 +/- 6.12 ng/mL, range 3.7-20.2; controls 2.46 +/- 0.49, range 1.5-2.9). sFasL was detected during five rMAS episodes (0.70 +/- 0.49 ng/mL, range 0.16-1.28; controls all below the limit of detection of 0.1). In addition, both parameters decrease during convalescence, reflecting clinical evolution. In conclusion, sFas seems to be consistently elevated during acute rMAS. sFasL is detected only in a subgroup of our adult rMAS patients extending the recent finding of sFasL elevation in a majority of children with macrophage activation syndromes (Hasegawa et al. Blood 1998;91(8):2793-2799). By interfering with AICD, sFas and sFasL might contribute to the pathogenesis of at least a subset of rMAS.     

Increased levels of soluble Fas in serum from diabetic patients with neuropathy.

OBJECTIVE: The aim of this study was to investigate circulating soluble Fas (sFas) and Fas ligand (sFasL), two transmembrane glycoproteins involved in apoptosis, in the serum of diabetic patients.MATERIAL AND METHODS: We assessed sFas and sFasL serum levels in normal controls (n=15), and in both 42 diabetic patients without complications, or with predominant retinopathy or neuropathy, using sFas and sFasL specific ELISA method.RESULTS: sFasL serum levels were less than 0.1 ng/ml in normal controls and in each group of diabetic patients. In diabetic patients with a predominant neuropathy, sFas serum levels were significantly increased not only when compared with normal controls (13.5 +/- 3.6 ng/ml vs 7.1 +/- 1.1 ng/ml, p<0.001), but also when compared with patients without complications (vs 9.1 +/- 1.8 ng/ml, p<0.001) or with a predominant retinopathy (vs 8.7 +/- 1.9 ng/ml, p<0.001).CONCLUSIONS: These preliminary data suggest that a dysregulation of the Fas system in peripheral neuronal cells may be involved in the increase of sFas observed in diabetic patients with neuropathy.     

Soluble form of Fas and Fas ligand in serum and bronchoalveolar lavage fluid of individuals infected with human T-lymphotropic virus type 1

Human T-lymphotropic virus type 1 (HTLV-1) carriers are known to develop pulmonary complications characterized by T-lymphocytic alveolitis. The aim of this study was to determine the profile and role of soluble Fas (sFas) and sFas ligand (sFasL) in the lung of asymptomatic HTLV-1 carriers. We measured sFas and sFasL levels in serum and bronchoalveolar lavage fluid (BALF) of 16 seropositive asymptomatic HTLV-1 carriers and 32 healthy subjects. The serum levels of both sFas and sFasL were significantly higher in HTLV-1 carriers than in the control. In BALF, the percentage of lymphocytes and CD4 positive T-cells, and the levels of sFasL were also significantly higher in asymptomatic carriers than the control, but there were no significant differences in sFas levels between the two groups. There was a significant correlation between BALF sFasL levels and serum sFasL levels and percentage of CD4 positive T-cells in BALF. Our results suggest that the increased levels of sFasL in the lung of asymptomatic HTLV-1 carriers are associated with accumulation of CD4 positive T-cells, and that resistance to apoptosis in HTLV-1 infected T-cells and overproduction of sFasL could contribute to T-lymphocytic alveolitis by down-regulating Fas-FasL mediated apoptosis.     

The levels of serum-soluble Fas in patients with rheumatoid arthritis and systemic sclerosis

Different defects in Fas/APO-1 interaction with its ligand or in signaling of apoptosis may contribute to autoimmune disease. The aim of this study was to examine whether elevated serum-soluble Fas (sFas) levels are associated with rheumatoid arthritis (RA) or systemic sclerosis (SSc). sFas level was assayed using a sandwich ELISA in serum from 37 patients with RA, 30 patients with SSc and 20 healthy controls. The RA patients were classified according to disease activity, anatomical joint damage, and the presence of pulmonary involvement. Presence of pulmonary fibrosis, CO diffusion capacity (DLCO) and skin score were determined in patients with SSc. Serum sFas levels were not significantly different between study groups. Serum sFas level in the active RA patients was significantly higher than in the patients with inactive disease (p<0.05). The untreated active RA patients had significantly higher sFas level than healthy controls (p<0.05). In RA patients, sFas level was significantly correlated with rheumatoid factor titer (p=0.01), C-reactive protein (p<0.05), and erythrocyte sedimentation rate (p<0.05). The RA patients with severe joint damage had significantly higher sFas level than those with mild joint damage (p<0.05). The untreated SSc patients had significantly higher sFas levels than the treated SSc patients and healthy controls (p<0.01). Serum sFas level was not correlated with presence of pulmonary fibrosis, DLCO or skin score. The soluble Fas molecule may provide a useful additional marker for assessment of disease activity and severity in patients with RA.Abbreviations CRP C-reactive protein - DLCO CO diffusion capacity - ESR Erythrocyte sedimentation rate - RA Rheumatoid arthritis - RF Rheumatoid factor - sFas Serum-soluble Fas - SSc Systemic sclerosis     

Stromelysin-1 (MMP-3) in synovial fluid of patients with rheumatoid arthritis has potential to cleave membrane bound Fas ligand

OBJECTIVE: To investigate the relationship between matrix metalloproteinases (MMP) and the soluble form of Fas ligand (sFasL) in the synovial fluid (SF) of patients with rheumatoid arthritis (RA), and to determine which MMP have a major role in cleaving FasL. METHODS: The concentrations of sFas and sFasL in SF from 48 patients with RA and 43 patients with osteoarthritis (OA) were measured using specific ELISA. The levels of different MMP (MMP-1, 2, 3, 7, 9) in SF were also measured by ELISA. The active forms of gelatinases were detected by gelatin zymogram. Human FasL-expressing transfected cells (hFasL/L5178Y) were used to investigate whether FasL is cleaved from membrane bound FasL. RESULTS: Significantly higher levels of MMP-1, 3, and 9 were found in SF from RA patients compared to OA patients, but MMP-7 was not detectable in either group. The concentrations of sFas and sFasL in SF were also higher in RA than in OA patients. However, there was no relationship between the concentration of sFas and sFasL. Among MMP, MMP-3 concentrations in SF were closely correlated with the level of sFasL and with disease activity of RA. Enzymatic cleavage assay indicated that MMP-3 has potential to cleave the FasL expressed on hFasL/L5178Y cells and to produce sFasL. CONCLUSION: There was significant correlation between the concentration of sFasL and MMP-3 in SF of patients with RA. In addition, our data indicate that the shedding of FasL may be regulated by MMP-3 in the joint of patients with RA.     

Overexpression of HBxAg in hepatocellular carcinoma and its relationship with Fas／FasL system

AIM: To study the expression and serum level of HBxAg,Fas and FasL in tissues of HCC patients, and to assess the relationship between HBxAg and Fas/FasL system.METHODS: Tissues from 50 patients with HCC were tested for the expression of HBxAg, Fas and FasL by S-P immunohistochemistry. Serum levels of sFas/sFasL and HBsAg/HBeAg were measured by ELISA assay. HBV X gene was detected by PCR in serum and confirmed by automatic sequencing. Fifty cases of liver cirrhosis and 30 normal controls were involved in serum analysis.RESULTS: The expression of HBxAg, Fas and FasL in carcinoma tissues was 96 %, 84 % and 98 %, respectively.Staining of HBxAg, Fas and FasL was observed predominately in cytoplasms, no significant difference was found in intensity between HBxAg, Fas and FasL (P＞0.05). HBxAg, Fas and FasL might express in the same area of carcinoma tissues and this co-expression could be found in most patients with HCC. The mean levels of sFas in serum from HCC, cirrhosis and normal controls were 762.29±391.56 μg@ L-1 835.36±407.33 μg@L-1 and 238.27±135.29 μg@L-1. The mean levels of sFasL in serum from HCC, cirrhosis and normal controls were 156.36±9.61iμg@ L-1, 173.63±18.74 μg@L-1 and 121.96±7.83 μg@ L-1.Statistical analysis showed that both sFas and sFasL in HCC and cirrhosis patients were significantly higher than those in normal controls (P＜0.01). Serum HBV X gene was found in 32 % of HCC patients and ,46 % of cirrhotic patients.There was no significant relationship between serum level of sFas/sFasL and serum X gene detection (P＞0.05). Eight percent of HCC patients with negative HBsAg and HBeAg in serum might have X gene in serum and HBxAg expression in carcinoma tissues.CONCLUSION: Our data suggest that HBxAg and Fas/FasL system plays an important role in the development of human HCC. Expression of HBxAg can leads to expression of Fas/FasL system which and reverse apoptosis of hepatocellular carcinoma induced by FasL.